| DOI | Resolve DOI: https://doi.org/10.1517/17460441.2015.974545 |
|---|
| Author | Search for: Stanimirovic, Danica B.1 ; Search for: Bani-Yaghoub, Mahmud2 ; Search for: Perkins, Martin2 ; Search for: Haqqani, Arsalan S.1 |
|---|
| Name affiliation | - National Research Council Canada. Human Health Therapeutics
- National Research Council Canada
|
|---|
| Format | Text |
|---|
| Type | Article |
|---|
| Journal title | Expert Opinion on Drug Discovery |
|---|
| ISSN | 1746-0441 |
|---|
| Volume | 10 |
|---|
| Issue | 2 |
|---|
| Pages | 141–155; # of pages: 15 |
|---|
| Subject | biomarkers; blood–brain barrier; in vitro blood–brain barrier models; stem cells |
|---|
| Abstract | The majority of therapeutics, small molecule or biologics, developed for the CNS do not penetrate the blood–brain barrier (BBB) sufficiently to induce pharmacologically meaningful effects on CNS targets. To improve the efficiency of CNS drug discovery, several in vitro models of the BBB have been used to aid early selection of molecules with CNS exposure potential. However, correlative studies suggest relatively poor predictability of in vitro BBB models underscoring the need to combine in vitro and in vivo BBB penetration assessment into an integrated preclinical workflow. |
|---|
| Publication date | 2014-11-12 |
|---|
| Publisher | Taylor & Francis Group |
|---|
| Terms of use | |
|---|
| Language | English |
|---|
| Peer reviewed | Yes |
|---|
| NRC number | NRC-HHT-53275 |
|---|
| NPARC number | 21275154 |
|---|
| Export citation | Export as RIS |
|---|
| Report a correction | Report a correction |
|---|
Record identifier | ba8b53a4-5b2c-4342-bb48-92ee7f85c7c1 | | Record created | 2015-05-21 |
|---|
| Record modified | 2016-05-09 |
|---|
